In Brief Xu et al. develop an efficient genomeediting technique in genetically recalcitrant clinical and environmental P. aeruginosa strains by exploiting their endogenous type I-F CRISPR-Cas system. Employing the technique, they identify underlying resistance mechanisms of an epidemic MDR genotype, PA154197, efficiently and develop anti-resistance strategies based on collateral sensitivity.
INTRODUCTION
Antimicrobial resistance (AMR) is imposing an alarming threat on global public health. Particularly challenging are those ''ESKAPE'' pathogens that constitute the major sources of nosocomial infections with extraordinary drug resistance (i.e., Enterococcus spp., Staphylococcus aureus, Klebsiella spp., Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) . Among them, Pseudomonas aeruginosa is recognized as a prototypical multidrug-resistant (MDR) path-ogen owing to both its intrinsic resistance to a variety of antimicrobials and its enormous capacity to develope acquired resistance during antibiotics chemotherapies (Oliver et al., 2015; Poole, 2011; Santajit and Indrawattana, 2016; Stover et al., 2000) . Remarkably, in recent years, MDR international high-risk clones of P. aeruginosa have emerged and caused worldwide outbreaks (Oliver et al., 2015) . Hence, it is of paramount importance to deeply understand the resistance mechanisms of these clones and develop anti-resistance treatment strategies. However, these studies are frequently impeded because of the lack of genetic-editing tools in the clinical P. aeruginosa genotypes.
P. aeruginosa is a ubiquitous pathogen capable of causing a wide array of acute and chronic infections. The species is notorious for its unusually large (ca. 6.4 Mbp) genome and extraordinarily diverse genotypes (Silby et al., 2011) . As a result, genetic tools established in the model strains, such as PAO1 and PA14, are often inapplicable in the clinical, environmental, and biotechnological strains of interest. Moreover, clinical MDR clones often contain a complex set of resistance markers originating from both chromosomal gene mutations and transferable elements (Cabot et al., 2012; Hocquet et al., 2003) , further limiting the conventional antibiotic-resistance-marker-based genetic manipulations. On the other hand, studies have indicated that the genetic background of resistant strains and epistasis among different resistant mutations plays an important role in the resistance levels of the strains and affects the effectiveness of antibiotic chemotherapies (Moura de Sousa et al., 2017; Vogwill et al., 2014 Vogwill et al., , 2016 . Hence, it is highly desirable to develop genome-editing techniques compatible with the genotypes of the strains of interests and to characterize AMR in the native genetic background of clinical strains.
In addition to being recognized as a prototypical MDR pathogen, P. aeruginosa is also an important model organism for understating CRISPR-Cas functions, especially the most widespread type I CRISPR-Cas system (van Belkum et al., 2015) . To exert its functions in the adaptive immune process in bacteria, the Cas proteins specifically bind to and cleave the invader DNA based on Watson-Crick base pairing between a small CRISPR RNA (crRNA) and its DNA target (Barrangou et al., 2007; Hille et al., 2018) . Conceivably, by modifying the sequence of the RNA guide, the Cas nucleases can be reprogrammed to cleave a specific genomic site and be exploited for genome editing upon a repair template is provided (Jinek et al., 2012) . Phylogenetic analysis has revealed that CRISPR-Cas systems are widely distributed in global AMR P. aeruginosa isolates with 70% of them belonging to the I-F subtype (van Belkum et al., 2015) . In recent years, repurposing the broadly distributed native CRISPR-Cas systems is emerging as a new CRISPR-based genome-editing strategy in prokaryotes. For instance, the native type I-B CRISPR-Cas system was harnessed for genome editing in the medically and industrially important species Clostridium tyrobutyricum and Clostridium pasteurianum, which frequently suffer from a poor DNA homeostasis and have a low genome-editing efficiency using the traditional allelic exchange or the heterologous CRISPR-Cas9 system (Pyne et al., 2016; Zhang et al., 2018) . The endogenous type I-E CRISPR-Cas system was successfully repurposed for genome editing in the commensal bacterium Lactobacillus crispatus, which was formerly genetically recalcitrant (Hidalgo-Cantabrana et al., 2019) . However, there has been no report about exploitation of native CRISPR-Cas systems for genome editing and functional genomics in the prototypic pathogen P. aeruginosa.
Previously, we have isolated an epidemic MDR P. aeruginosa clinical strain, PA154197, that shares a clonal complex with two international cystic fibrosis (CF) isolates and displays a comparable resistance profile to the high-risk clone ST175 (Cao et al., 2019) . Employing the allelic exchange and the heterologous CRISPR-Cas9-based method failed to deliver desired mutations for resistance characterizations in this strain. As in the majority of clinical and environmental isolates of P. aeruginosa, PA154197 is found to contain a native type I-F CRISPR-Cas loci. Hence, in this study, we use PA154197 as a model to explore the native type I-F CRISPR-Cas-based genome editing in a clinical MDR P. aeruginosa genotype and its exploitation in the functional genomics of MDR. A highly efficient, one-step (for non-essential gene allele) or two-step insert-delete (In-Del) (for essential gene allele or inefficiently targeted genome site) genome-editing technique was successfully developed. The editing pipeline was readily applicable in additional clinical and environmental P. aeruginosa strains tested that contain the endogenous type I-F CRISPR-Cas system. Employing the technique, we unveiled the extraordinary resistance capacity of PA154197 and developed an advanced treatment strategy against this clinical MDR isolate. These studies provided a framework for understanding and control of clinical resistant pathogens.
RESULTS

Functionality of the Native Type I-F CRISPR-Cas Locus in PA154197
Analysis of the CRISPR loci in PA154197 identified the signature cas8f gene and the unique cas2-cas3 fusion ( Figure 1A ) (Richter et al., 2012) , indicating that the loci encode a typical type I-F CRISPR-Cas system. The cas operon of the system was found to be sandwiched by two convergent CRISPR arrays with 4 and 10 spacers, respectively. Their consensus repeat sequence differs by only one nucleotide, and their spacers are nearly identical in size (32 bp) ( Figure 1A ). In addition, a number of spacers show significant homology to phage or putative prophage sequences (data not shown), implying the adaptive immune activity of the endogenous CRISPR-Cas system. To harness the system for genome editing, we first assessed its genome-targeting activity. We selected mexB as the target gene for this purpose, which encodes the inner-membrane component of the housekeeping efflux pump MexAB-OprM. Previous studies have revealed that the canonical target of the type I-F CRISPR-Cas system is 5 0 -protospacer-GG-3 0 with 5 0 -GG-3 0 serving as the protospacer adjacent motif (PAM) sequence (Cady et al., 2012; Richter et al., 2014) . Noticeably, because the crRNA guides the base pairing with the complement 5 0 -protospacer-GG-3 0 sequence in the target, earlier studies defined 5 0 -GG-3 0 as the PAM. However, it was recently proposed to follow the guide-centric (5 0 -CC-3 0 ), rather than the target-centric (5 0 -GG-3 0 ), terminology (Leenay and Beisel, 2017) . Therefore, hereafter the PAM is described as 5 0 -CC-3 0 . Thus, an internal 32-bp nucleotide preceded by a 5 0 -CC-3 0 PAM corresponding to the C74-C105 region in mexB was selected as the target (PAM protospacer). To achieve specific targeting to this genomic region by the native CRISPR-Cas machinery in PA154197 cells, an artificial mini-CRISPR encompassing the selected 32-bp internal sequence flanked by two 28-bp repeats was assembled. To construct a plasmid-based tool enabling expression and delivery of the mini-CRISPR into PA154197 cells, a strong promoter Ptat (Shah, 2014) was selected to drive the expression of the mini-CRISPR and the expression cassette was cloned into the pMS402 vector upstream of the lux genes (Olsen et al., 1982) . Along with the kanamycin resistance marker on the vector, this plasmid tool allows an antibiotic-luminescence dual selection of the transformants ( Figure 1B ). The resulting plasmid pAY5233 is termed the targeting plasmid in the editing method we developed ( Figure 1B ). Transformation of pAY5233 into PA154197 cells yielded no transformants recovery compared with the high transformation efficiency of the control plasmid pAY5211, which lacks the mini-CRISPR array ( Figure 1C ), implying the occurrence of the detrimental chromosome cleavage in the pAY5233-containing cells. This result verified that the native CRISPR-Cas system in PA154197 is active to interfere genomic DNA.
Harnessing the Native Type I-F CRISPR-Cas System to Delete the AMR Gene mexB To exploit the system for gene deletion (DmexB as an example), we then assembled a 1-kb donor sequence consisting of 500-bp upstream and 500-bp downstream homologous arms of mexB and inserted it into pAY5233 to yield pAY5235 ( Figure 1D ), which is termed the editing plasmid in our method. The transformation recovery rate of pAY5235 into PA154197 cells was significantly increased compared to that of the targeting plasmid pAY5233 ( Figure 1C ), suggesting the occurrence of homologous recombination by the provision of the repair donor. Since the plasmid tool contains a Ptat-driven lux cassette, luminescence was utilized to assist in the screening of positive clones. Eight luminescent colonies were selected for validation and four colonies showed the desired, scarless, and precise mexB deletion (3 kb) in the chromosome ( Figures 1E and 1F ).
The success rate increased to more than 90% when the size of the desired gene deletion was decreased to 1 kb (Figures S1A and S1B), which is the average size of prokaryotic genes (B) Schematic showing the design and working mechanism of the mexB-targeting plasmid (pAY5233). The mini-CRISPR in pAY5233 comprises a 32-bp spacer (blue) flanked by two repeats (yellow) co-expressed with the reporter lux operon (green) under the control of the strong promoter Ptat. The PAM sequence is framed. (C) Representative plates showing the transformation efficiency of the vector control pAY5211, the targeting plasmid pAY5233, and the editing plasmid pAY5235. (D) Design and working mechanism of the editing plasmid pAY5235 containing both a self-targeting CRISPR and a repair donor for mexB deletion. The donor sequence (pink) consisting of 500 bp upstream (U1) and downstream (D1) of mexB is shown. (E) Eight randomly selected transformants were subjected to colony PCR to screen for the DmexB mutants (positive clones are highlighted in red). Primers used in colony PCR (F1/R1) are indicated in (B). (F) The screened DmexB mutants in (E) were further validated by DNA sequencing. See also Figures S1 and S2. (Xu et al., 2006) . Furthermore, the plasmid tool can be readily cured following culturing of the edited cells in the absence of the antibiotic (kanamycin) pressure overnight ( Figure S2 ), suggesting the feasibility of multiple rounds of genome editing using the programmable editing plasmid. Further studies revealed that the technique was readily applicable in two additional type I-F CRISPR-containing clinical and environmental P. aeruginosa strains, PA150567 and Ocean-100 ( Figure S1C ), demonstrating the applicability of the technique in a broad range of P. aeruginosa strains isolated from different sources.
Simultaneous Overexpression of the MexAB-OprM and MexEF-OprN Efflux Pumps Constitutes the Major Resistant Determinants in PA154197
Employing the established genetic-editing technique, we first constructed DmexB, DmexF, and DmexH mutants and examined the contribution of three multidrug efflux pumps MexAB-OprM, MexEF-OprN, and MexGHI-OpmD to the resistance profile of PA154197, which were shown to be overexpressed by transcriptome analysis (Cao et al., 2019) . DmexB led to a downshift of minimum inhibitory concentrations (MICs) of all antipseudomonal antibiotics tested ( Figure 2 ; Table S1 ) with greater fold changes occurring to the antipseudomonal b-lactams and penicillin-b-lactamase inhibitor combinations, i.e., CAR (> 128-fold), CAZ (8-fold), MEM (> 32-fold), ATM (64-fold decrease), TZP (64-fold), than to the fluoroquinolones LVX (2-fold) and CIP (2-fold). DmexF led to downshift of MICs of antipseudomonal fluoroquinolones (FQs), i.e., LVX (2-fold) and CIP (4-fold), which is consistent with the substrates profile of the two pumps revealed by ectopic overexpression of the genes in laboratory strain PAO1 (Kö hler et al., 1997) . Unexpectedly, deletion of mexH did not lead to any detectable difference in the MICs of all the antibiotics and antimicrobial agents tested ( Figure 2 ; Table S1 ). Further deletion of mexH in the DmexB DmexF strain background showed no change on MIC either (data not shown), suggesting that the MexGHI-OpmD pump does not contribute to the resistance development in PA154197.
We further constructed DmexB DmexF double deletion to investigate the additive effect of the two pumps, if any. MICs of antipseudomonal b-lactams in the double-deletion strain were similar to those in the DmexB single-deletion strain, suggesting that b-lactam resistance was largely caused by the MexAB-OprM pump in PA154197. Remarkably, MICs of antipseudomonal FQs were found to be dramatically decreased in the double-deletion cells compared to those in the DmexB and DmexF single-deletion cells ( Table S1 ). The MIC fold change of the two FQs (32-fold) was much greater than the multiply of the MIC fold change caused by DmexB (2-fold) and of DmexF (2-4-fold) alone, suggesting the synergy of the two pumps to expel fluoroquinolones. We next assessed the synergy by calculating the fractional inhibitory concentration index (FICI) (Gonzales et al., 2015) of the DmexB DmexF combination against the antibiotics tested ( Figure 2 ). The FICI value < 0.5 indicates obvious synergy; a FICI value of 0.5-1.0 indicates partial synergy and a FICI value of 1.0-4.0 indicates indifference. The FICI values of the DmexB DmexF combination against LVX and CIP were found to be 0.125 and 0.188, respectively, suggesting substantial synergy of the two pumps to expel FQs ( Figure 2 ). Disk diffusion testing showed the similar trend of susceptibility changes in these mutant strains ( Figures S3A and S3B ). Analysis of growth curves of these strains in the absence of antibiotics suggested that the observed MIC alterations were not caused by growth differences ( Figure S3C) . 
. Profile of Antimicrobial Susceptibility Changes Caused by Various Reverse Mutations and Their Synergy Denoted by FICI Values
MICs of 12 antimicrobial agents (8 antipseudomonal antibiotics and 4 other antimicrobial agents) were tested in 12 PA154197 isogenic mutants. MIC fold changes of the mutants relative to the wild-type PA154197 are expressed by the color key shown (detailed MIC values are shown in Table S1 ). FICI values of various mutation combinations against the antimicrobial agents tested are presented in numbers. FICI values below 0.5 that indicate synergy are highlighted in orange. See also Figure S3 and Tables S1 and S2. in this mutant are still higher than in the control strain PAO1 (MIC of both LVX and CIP is 0.25), suggesting the presence of additional FQ resistance determinants in PA154197. A T248C substitution (corresponding to T83I) in the quinolone resistance determining region (QRDR) (Varughese et al., 2018) of the DNA gyrase gene gyrA was identified in PA154197 ( Figure S4A ). To examine whether this mutation confers further FQ resistance in PA154197, we set out to replace the gyrA gene with that in PAO1, i.e., to construct PA154197 gyrA PAO1 . Since gyrA is an essential gene that could not be interfered, we employed an auxiliary PAM located 475 bp downstream of gyrA as the target and developed a two-step In-Del strategy to edit this allele (Figure 3) . Exploiting the auxiliary PAM, we conducted the first round of editing to insert a 32-bp short tag between the PAM and the protospacer. gyrA gene replacement was achieved subsequently in the second round of editing when the short tag was deleted by using the same PAM as in the first step but with a different protospacer sequence (the tag). This time, a donor sequence lacking the tag but containing the desired PAO1 gyrA gene sequence was provided to achieve the gene replacement ( Figure 3 ). MICs of LVX and CIP in the resulting strain gyrA PAO1 were 8-and 4-fold lower than in the PA154197 parent ( Figure 2 ; Table S1 ), suggesting that gyrA mutation indeed contributes to the FQ resistance in PA154197.
Mutations in mexR and mexT Lead to Simultaneous Overexpression of the mexAB-oprM and mexEF-oprN Efflux Genes Overexpression of efflux genes is often caused by mutations in their transcription regulators ( Figure 4A ). To examine whether a single nucleotide substitution G226T in the transcription repressor gene mexR identified in PA154197 ( Figure S4B) is responsible for the overexpression of mexAB-oprM, we constructed the reverse point mutation mexR T226G, which was designated as mexR PAO1 . The transcriptional level of mexAB genes in the mexR PAO1 mutant was reduced to a similar level to PAO1 ( Figure 4B ), suggesting that the G226T mutation in mexR that introduced a stop codon into MexR following the E76 residue accounts for the overexpression of mexAB-oprM in PA154197. Both MIC analysis and the disk diffusion test confirmed this result ( Figure S3 ; Table S1 ).
The mexT gene encodes a transcription activator of the mexEF-oprN efflux system ( Figure 4A ) (Kö hler et al., 1999 ). An 8-bp deletion in mexT that was previously described as an nfxC type resistant mutation (Linares et al., 2005; Maseda et al., 2000) is identified in PA154197 ( Figure S4C ). We then employed the two-step In-Del strategy described above to construct the reverse mutation of 8-bp insertion because the nucleotides sequence of the PAM protospacer for the desired editing site in mexT contains two 6-bp repeats, which occluded efficient CRISPR recognition and caused failure of DNA interference ( Figures S5A and S5B ). The resulting mutant was designated as mexT PAO1 . Both transcription of mexEF ( Figure 4C ) and the MICs of LVX and CIP in the mexT PAO1 cells were reduced compared to the wild-type (WT) PA154197 (Table S1), indicating that the nfxC type 8-bp deletion in mexT is responsible for the overexpression of mexEF-oprN. Notably, in several non-MDR genotypes, overexpression of the MexEF-OprN pump by MexT in the nfxC type P. aeruginosa was reported to lead to antagonistic impairment of the MexAB-OprM pump and a hyper-susceptibility to its substrates b-lactams ( Figure 4A ) (Maseda et al., 2004; Mulet et al., 2011) . The fact that the nfxC type mutation-containing PA154197 cells over-produce the MexAB-OprM pump and are resistant to b-lactams suggests that either the mexR G226T mutation or additional compensatory mutation in PA154197 suppressed the MexT-mediated repression of MexAB-OprM ( Figure 4A ).
Consistent with its role of simultaneously repressing another AMR gene oprD that encodes an outer-membrane (OM) porin protein ( Figure 4A ), the reverse mutation mexT PAO1 also led to a 3-fold-higher transcription of oprD than the PA154197 parent ( Figure 4C ) and a restored susceptibility to imipenem (IPM), whose entry is dependent on the OprD portal (Figure S3 ). In the case of another AMR gene, parS, that was proposed to also regulate mexEF-oprN system (Wang et al., 2013) , reverse mutation of a nonsynonymous nucleotide substitution, G1193A, in the gene (Cao et al., 2019) did not lead to any susceptibility changes to various antibiotics (Table S1 ), suggesting that this mutation does not contribute to the resistance development in PA154197.
Extensive Resistance Synergy and Multiplication Networks Shape the Clinically Significant MDR in PA154197
We next constructed a series of double-and triple-reverse mutations and examined the interplay of the different resistance determinants. Reverse of all three resistance mutations identified (i.e., gyrA PAO1 , mexR PAO1 , and mexT PAO1 ) led to the complete loss of antibiotics resistance and an overall drug susceptibility profile similar to that of PAO1 ( Figure 2 ; Table S1 ), confirming that these three genetic mutations underlie the resistance development in PA154197. FICI values of the gyrA PAO1 -mexR PAO1 -mexT PAO1 triple combination against the LVX and CIP were calculated to be 0.156 and 0.047, respectively (Figure 2) , indicating substantial and extensive synergy of all three determinants to confer the hyper FQ resistance in PA154197. FICI values of the series of reverse-mutation combinations against several non-antipseudomonal antibiotics revealed the strong synergy of overproduction of the two pumps to confer TMP (FICI = 0.094) and CHL (FICI = 0.063) resistance as well and partial synergy toward CRO (FICI = 0.625) and TET (FICI = 0.625) resistance in PA154197.
On the other hand, resistance to antipseudomonal b-lactams including the penicillin-b-lactamase inhibitor combination was almost exclusively dependent on the activity of the MexAB-OprM pump in PA154197. The series of isogenic reverse mutants constructed allowed assessing the relative contribution of basal-level MexAB-OprM and MexAB-OprM over-production to the b-lactams resistance, which can be calculated with the formulas MIC mexR PAO1 /MIC DmexB and MIC WT /MIC mexR PAO1 , respectively. The results suggested that resistance to the antipseudomonal penicillin CAR was largely conferred by basal-level MexAB-OprM (64-fold MIC change by basal-level pump versus 2-fold by over-produced pump) (Table S2) , whereas resistance to the monobactam ATM was largely contributed by the overproduction of the MexAB-OprM pump (16-versus 4-fold) ( Table  S2 ). The FQ resistance conferred by the MexAB-OprM pump was also attributed to the over-production of the pump (Table  S2 ). Together, these results illustrated the robust interplay among the various types and levels of resistance determinants in PA154197 to confer clinically significant MDR.
PA154197 Displays Collateral Sensitivity to Small
Cationic Peptidomimetics in a mexT-Dependent Manner MDR represents the major obstacle in the therapeutics of P. aeruginosa infections. To combat drug-resistant infections, it is necessary to both develop new antibiotics and to potentiate the existing antibiotics and preserve the current antibiotics pipeline. Fortuitously, when we attempted to employ the efflux pump inhibitor phenyl-arginine-beta-naphthylamide (PAbN) to treat PA154197, we found that the strain is fairly sensitive to this compound with a MIC value of 16 (mg/ml) ( Figure 5A ), much lower than the working concentration of the compound (50 mg/ml) to inhibit the basal-level efflux activity (Lamers et al., 2013) . Importantly, we found that PA154197 displays a much higher PAbN susceptibility than the control strain PAO1 (MIC > 128). Further analysis of the series of isogenic mutants that reversed one, two, or all three key resistant determinants revealed that their PAbN susceptibilities were intermediate (MIC = 32-128) compared with the PA154197 parent and the reference strain PAO1. The PAbN susceptibility profile of these strains was opposite of that of antibiotics ( Figure 5A ), indicating that stepwise acquisition of resistance mutations against antibiotics rendered PA154197 susceptible to PAbN. This pattern reflected a phenomenon called ''collateral sensitivity,'' i.e., evolved resistance is costly and resistance mutations to one class of antibiotics may exacerbate susceptibility against other antibiotics or agents (Szybalski and Bryson, 1952) . Despite being verified in a series of laboratory-evolved resistant strains of E. coli and P. aeruginosa (Barbosa et al., 2017; Gonzales et al., 2015; Lá zá r et al., 2018; Pá l et al., 2015; Podnecky et al., 2018; Wambaugh et al., 2017) , no systematic investigation and collateral sensitivity has been reported in clinical MDR strains. Our data above indicated that PA154197 displayed collateral sensitivity to PAbN. To further investigate this, we also measured the MICs of other clas-ses of antibiotics including aminoglycosides (streptomycin and gentamycin), non-ribosomal peptides (Polymyxin B and colistin), fosfomycin, and the antimicrobial peptide GF-17 against these strains, but found none of them displayed collateral effects against PA154197 (Table S1 ). Furthermore, we found that the collateral effect of PAbN against PA154197 is dependent on the mexT gene, as replacing the mexT allele with the PAO1 mexT (mexT PAO1 ) abolished the susceptibility of PA154197 to PAbN ( Figure 5A ). Similar abolishment of the collateral sensitivity was observed in all mutants containing mexT PAO1 ( Figure 5A) . Notably, this effect is independent of the capacity of MexT to activate the mexEF-oprN efflux pump as neither DmexF nor DmexB DmexF double deletion abolished the sensitivity of the strain to PAbN. Since MexT also regulates the OM porin gene oprD and PAbN was indicated to also act on the P. aeruginosa OM to increase its permeability (Lamers et al., 2013) , we speculated that the mexT-dependent collateral sensitivity in PA154197 is due to its altered OM features relative to PAO1. To address this, we employed an OM-sensitive probe PI-BactD (Long et al., 2019) to monitor the OM features of PA154197 and PAO1 cells and the cells treated by PAbN. Signals corresponding to PA154197 and PAO1 cells were distinctive in the 2D output graph of the sensor (Figure 5B ), suggesting the different physical chemical features of their OM. Furthermore, an obvious signal shift was recorded in the PA154197 population upon PAbN treatment, whereas no signal shift was observed in the PAO1 population in response to the same PAbN treatment ( Figure 5B) , confirming that the higher susceptibility of PA154197 to PAbN compared to PAO1 was due to the higher susceptibility of its OM to the perturbation by PAbN. Consistent with this, an insertion mutation in the porin gene oprD that potentially perturbs the OM of PA154197 cells further increased the sensitivity of the resulting cells to PAbN (MIC = 8) ( Figure 5A ). Furthermore, sub-inhibitory concentration of PAbN (7.5 mg/ml) was sufficient to sensitize PA154197 to the bulky, anti-Grampositive antibiotic vancomycin (MIC = 2) (Table S3 ), which normally is incapable of crossing the OM of Gram-negative bacteria due to the membrane permeability barrier and hence is inactive to Gram-negative cells. Supplement of Mg 2+ , which stabilizes the OM, reversed this effect, i.e., restored resistance to vancomycin (Table S3 ).
To further confirm the hyper-sensitivity of PA154197 to small, cationic compounds, we tested and compared the sensitivity of PA154197 and PAO1 to another cationic peptidomimetic we developed: (R)-N-(4-(tert-butyl)thiazol-2-yl)-2-chloro-5-(2,6-diaminohexanamido) benzamide (H-31) (Yamaguchi et al., 2017) . PA154197 indeed displayed 32fold lower MIC to H-31 than PAO1 (Table S3 ). Likewise, sub-inhibitory concentration of H-31 (2 mg/ml) was sufficient to sensitize PA154197 to vancomycin and Mg 2+ abolished this effect. These results together strongly indicated that acquisition of drug resistance in PA154197 rendered the collateral sensitivity of the cells to small, cationic peptidomimetics due to OM perturbation.
PAbN and H-31 Potentiate Antipseudomonal Antibiotics against the MDR Strain PA154197
We next exploited the identified collateral effect to treat the clinical MDR strain PA154197. We first examined the MICs of various antibiotics against PA154197 in the presence of sub-inhibitory concentration of PAbN (7.5 mg/ml) and H-31 (2 mg/ml), respectively. Supplementing PAbN and H-31 led to 4-128-and 1-64-fold downshifts of MICs of all the antibiotics tested, respectively, demonstrating that PAbN and H-31 potentiates the activities of antibiotics against PA154197 ( Figure 6 ; Table S4 ). Supplementing the same concentration of PAbN and H-31 also led to the downshift of MICs of these antibiotics against the susceptible strain PAO1, but to a much smaller extent, i.e., 1-8-fold ( Figure 6 ; Table S4 ). Introduction of mexT PAO1 alleviated the antibiotics potentiation effect of PAbN and H-31 against PA154197 (Table S5) , further confirming the collateral effect of PAbN and H-31 against PA154197 and its genetic dependence on the mexT allele. The sensitivity curve showed that supplementing PAbN and H-31 rendered the MDR PA154197 cells susceptible to antibiotics, such as IPM and FOF, and the susceptibility was greater than the PAO1 cells (Figure 7) . To further examine the efficacy of collateral agents and antibiotics combinations against the MDR P. aeruginosa cells, we co-administrated 7.5 mg/ml PAbN or 2 mg/ml H-31 with two antibiotics, 4MIC IPM and 4MIC FOF, to PA154197 or PAO1 cell cultures and analyzed their killing kinetics. The combined treatment not only was more effective against the MDR strain PA154197 than against the susceptible strain PAO1 but also displayed an accelerated killing against PA154197 than against PAO1 ( Figure S6 ), demonstrating the applicability of the uncovered collateral sensitivity in anti-resistance interventions against clinical MDR strains.
DISCUSSION
Due to the difficulty of genetic manipulation in the clinical isolates of resistant pathogens, understanding of their resistance development has been largely based on comparative genomics and heterologous reconstitution in the laboratory model strains (Jia et al., 2017) . In this study, we established a single-plasmid-mediated, highly efficient genome-editing technique in the prototypic pathogen P. aeruginosa by harnessing the most common CRISPR-Cas system (type I-F) in the species. Compared with a recently reported heterologous Cas9-based genome-editing method in P. aeruginosa model strains that requires successive transformation of two editing plasmids (Chen et al., 2018) , and the conventional two-step allelic exchange method (Choi and Schweizer, 2005) , which is more laborious and results in an undesirable flippase recognition target (FRT) scar in the edited site, our method of using a one-step transformation of a single editing plasmid represents a more efficient and cleaner genome-editing technique, especially in those clinical and environmental strains suffering a poor DNA homeostasis. Combined with the two-step In-Del strategy, this technique enabled various non-lethal genetic manipulations in P. aeruginosa cells.
Employing this powerful editing technique, not only the key resistant determinants but also their synergy and multiplication networks underling the extraordinary antibiotic recalcitrance of PA154197 were identified. Two RND efflux pumps, MexAB-OprM and MexEF-OprN, are simultaneously over-produced and synergize the efflux of FQs, CHL, and TMP in PA154197. Interestingly, previous studies using genetic reconstitution in laboratory strains suggested that there is a lack of multiplicative or synergetic effects between over-expression of multidrug efflux pumps (Bruchmann et al., 2013; Horna et al., 2018; Kö hler et al., 1999; Li et al., 2015; Llanes et al., 2004; Riera et al., 2011) . Particularly, in the nfxC type P. aeruginosa strains, over-production of MexEF-OprN was found to be antagonistic to the MexAB-OprM pump. (Maseda et al., 2004; Mulet et al., 2011) . These results together suggested that clinical MDR P. aeruginosa strains might have developed compensatory mutations to overcome the fitness trade-off of overexpressing more than one of the efflux pumps, which warrants further investigations in the future.
Despite its increasing therapeutic implications in the treatment of drug-resistant pathogens (Barbosa et al., 2017 MICs of 13 antimicrobial agents (8 antipseudomonal antibiotics and 5 other antimicrobial agents) were tested in PAO1 and PA154197 in the presence and absence of PAbN (7.5 mg/ml) and H-31 (2 mg/ml), respectively. MIC fold changes following PAbN and H-31 supplementation in the PAO1 and PA154197 cells are denoted by the blue color key. Detailed MIC values in the strains and conditions are shown in Table S4 . Bryson, 1952; Wambaugh et al., 2017) , research about collateral sensitivity has largely focused on the laboratory-evolved strain lines that display resistance to specific classes of antibiotics, and little effort has focused on the clinically isolated MDR strains (Imamovic et al., 2018; Jansen et al., 2016) . The series of constructed isogenic mutants that mimic the sequential acquisition of the key resistance mutations enabled us to identify the collateral sensitivity of PA154197 to small cationic peptidomimetics due to its compromised OM permeability. Interestingly, a recent study on a set of 60 laboratory-evolved antibiotic-resistant E. coli also revealed a widespread collateral sensitivity of the resistant strains to the OM targeting agent antimicrobial peptides (Lá zá r et al., 2018) , suggesting that OM perturbation caused by resistance mutations may represent a common mechanism of collateral sensitivity in Gram-negative bacteria. However, unlike the set of 60 AMR E. coli strains, PA154197 does not show collateral sensitivity to cationic antimicrobial peptides, such as GF-17, or to cationic peptide antibiotics, such as PMB and CST, which disrupt Gram-negative bacteria OM by their interactions with lipopolysaccharide (LPS) molecules (Wang et al., 2015) , suggesting that different types of OM perturbations other than LPS modification occurred in PA154197.
Furthermore, we revealed that mexT is the key genetic determinant underlying the collateral sensitivity of PA154197 to small cationic peptidomimetics. Interestingly, a resistance mutation in the transcription regulator marR that simultaneously regulates the expression of the acrAB multidrug efflux pump gene and LPS modification genes in E. coli was found to underlie MIC assays for IPM (left) and FOF (right) sensitivity in PAO1 and PA154197 with or without the supplement of PAbN (7.5 mg/ml, bottom) . Data are represented as the mean ± SD (n = 3). See also Figure S6 and Table S4. the collateral sensitivity of the cells to antimicrobial peptides (Lá zá r et al., 2018) . Analogously, in addition to regulating the mexEF multidrug efflux pump, MexT is known to also regulate the porin gene oprD and a series of other genes in P. aeruginosa (Tian et al., 2009) . These results suggested that transcription regulators that simultaneously regulate membrane-associated resistance determinants and other membrane homeostasis genes may represent as the common genetic determinants of collateral sensitivity. These findings have important implications in characterizing collateral sensitivity in other Gram-negative resistant pathogens.
Lastly, we found that overexpression (40-fold higher than in PAO1) of the efflux gene mexH and nucleotide substitution in parS did not contribute to the drug resistance in PA154197. These results suggest that not all genetic variations in resistance genes lead to the development of antibiotic resistance phenotypes, further highlighting the importance and necessity of the targeted functional genomics in the genetic background of clinically resistant pathogens.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
STAR+METHODS KEY RESOURCES TABLE
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Aixin Yan (ayan8@hku.hk). This study did not generate new unique reagents.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
All the bacterial strains used and constructed in this study are listed in Table S6 . E. coli DH5a is used for plasmid propagation and is usually cultured at 37 C in Luria-Bertani (LB) broth or on the LB agar plate supplemented with 20 mg/ml Kanamycin (KAN). P. aeruginosa PA154197 was isolated from the Queen Mary Hospital in Hong Kong, China (Cao et al., 2019) . PA154197 and its derivatives were selected on LB agar plate with 500 mg/ml KAN.
METHOD DETAILS
Plasmid Construction
All the plasmids constructed and used in this study are listed in Table S6 . Mini-CRISPR element consisting of two repeats (GTTCACTGCCGTATAGGCAGCTAAGAAA) flanking the spacer (Spacer sequence, see Table S6 ) was synthesized by BGI (Shenzhen, China). PCR was performed using the iProof High-Fidelity DNA Polymerase (Bio-Rad, USA). Mini-CRISPR elements and plasmid pAY5211 were digested using the restriction enzymes KpnI and BamHI (NEB, USA) and ligated using the Quick Ligation TM Kit (NEB, USA). Donor sequences which typically contain 500-bp upstream and 500-bp downstream of the editing sites with 21-bp overlap of the XhoI-digested targeting plasmid at each end (See Donor-Up-F/Donor-Down-R in (Table S6) .
Transformation of PA154197
Electrocompetent PA154197 cells were prepared by inoculating a fresh colony in LB broth and grown at 37 C overnight with 220-rpm agitation. Following subculture (1:100 dilution) into 50 mL fresh LB broth and growing to OD 600 = 0.5-0.6, cells were collected by centrifugation at 4 C with 4,500 rpm for 15 min and washed three times with cold, autoclaved Milli-Q H 2 O. The resulting cells were resuspended into 1 mL Milli-Q H 2 O. 100 mL electrocompetent PA154197 cells were then mixed with 1 mg editing plasmid and subject to electroporation at 2.3 kV (BTX, USA). 1 mL cold LB broth was added to recover the cells. Following recovering at 37 C for 1.5 h with agitation, cells were pelleted and resuspended in 100 mL LB before spread onto the LB plates containing 500 mg/ml KAN. The plates were incubated at 37 C for 24 h.
Mutants Screening and Verification
Colonies were first subjected to luminescence screening using the Synergy HTX Plate Reader (Bio Tek, USA). Colonies with high luminescent intensity were further verified by colony PCR using Taq DNA polymerase (Thermal Scientific, USA) with indicated primers and DNA sequencing (BGI, China). Sequencing results were visualized using DNA sequencing software Chromas (Technelysium Pty Ltd, Australia)
Curing of Editing Plasmid P. aeruginosa cells underwent one round of editing was streaked onto the LB ager plate and incubated at 37 C overnight. Single colony was selected and the curing was verified by the failure of growth in LB broth with 100 mg/ml KAN. In some cases, multiple (2 to 3) rounds of streaking are required for the thorough plasmid curing.
Antibiotic Sensitivity Assays
Minimum inhibitory concentration (MIC) was measured in 96-well plate following the standard protocol of ASM with slight modification (Rankin, 2005) . Overnight culture was diluted and approximately 10 5 cells were inoculated in each well containing antibiotic with final concentrations ranging from 0.25 to 128 mg/ml. Following incubation at 37 C for 16-20 h, MIC values were determined as the lowest concentration of antibiotics that completely inhibit growth of bacteria as detected by the unaided eye. Growth measurement shown in Figure 7 was set up in exactly the same manner as the MIC assay, except that cultures were grown at 37 C in the Synergy HTX Plate Reader (Bio Tek, USA) for 12 h with agitation. Cell density (OD 600 ) at 12 h was selected to plot the sensitivity curves. Assays were performed in triplicate.
Quantitative reverse transcriptase PCR Bacterial cells from overnight culture were harvested by centrifugation at 4 C. Total RNA was extracted using RNeasy Mini Kit (QIAGEN, Germany) according to the manufacturer's instruction. Reverse transcription (RT) was performed using PrimeScript TM RT reagent Kit (Takara, Japan). Quantitative PCR was performed using specific primers and the SYBR TM Green PCR master mix (Applied Biosystems, USA) in a 20 mL reaction system. The reaction was performed in ABI StepOnePlus real time PCR system with recA and clpX as reference genes to normalize the relative expression of the target genes. The results were presented as fold change expression of the target genes, and results were presented as the mean of three independent biological isolates.
Disk Diffusion Assay 20 ml overnight culture was mixed with 5 mL melted LB top agar (0.75%) and poured on a LB agar plate. After the agar was solidified, round filter paper disks were placed. 5 ml antibiotic solution (2 mg/ml) was added to the center of the paper disks. The plates were incubated at 37 C for 16 h.
Fractional Inhibitory Concentration Index
Synergy of resistance determinants combinations was determined by calculating fractional inhibitory concentration index (FICI) values (Gonzales et al., 2015) . The MIC of double or triple reverse mutations is divided by the MIC of each of single mutation, yielding the fractional contribution of each mutation in the combination. Interaction of different resistance mutations (A, B, C) is scored using the following formula: FICI (ABC) = MIC (ABC) /MIC (A) + MIC (ABC) /MIC (B) + MIC (ABC) /MIC (C) .
PI-BactD Assay
Overnight P. aeruginosa culture was diluted to OD 600 = 0.01 in fresh LB medium in the presence or absence of PAbN (7.5 mg/ml). Diluted cell culture was incubated at 37 C with 220-rpm agitation. Cells were harvested when OD 600 reaches 2.0 by centrifugation and washed twice using PBS buffer (10 mM, pH 7.2). The bacterial cell pellets were re-suspended in PBS to OD 600 as 0.4. PI-BactD was added into 1 mL cell suspension to a final concentration of 10 mM. Output signals of two channels: fluorescence increase (DS/S 0 ) and fluorescence ratiometric changes (I 482 /I 375 ) were recorded to plot the 2D graph. Six replicates were conducted for each strain and treatment.
